

Matthias Eiber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8200963/publications.pdf>

Version: 2024-02-01

179
papers

10,705
citations

36203

51
h-index

34900

98
g-index

181
all docs

181
docs citations

181
times ranked

6545
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer. <i>Asian Journal of Urology</i> , 2022, 9, 69-74.	0.5	6
2	Tumor Sink Effect in ⁶⁸ Ga-PSMA-11 PET: Myth or Reality?. <i>Journal of Nuclear Medicine</i> , 2022, 63, 226-232.	2.8	42
3	Whole-body uptake classification and prostate cancer staging in ⁶⁸ Ga-PSMA-11 PET/CT using dual-tracer learning. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 517-526.	3.3	23
4	The added value of PSMA PET/MR radiomics for prostate cancer staging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 527-538.	3.3	38
5	Pretherapeutic Comparative Dosimetry of ¹⁷⁷ Lu-rhPSMA-7.3 and ¹⁷⁷ Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 833-839.	2.8	13
6	Head-to-Head Comparison of ⁶⁸ Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial. <i>Journal of Nuclear Medicine</i> , 2022, 63, 847-854.	2.8	43
7	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 76-80.	2.8	20
8	Utility of ¹⁸ F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1334-1342.	2.8	15
9	Initial evaluation of [¹⁸ F]-FACBC for PET imaging of multiple myeloma. <i>EJNMMI Research</i> , 2022, 12, 4.	1.1	4
10	Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. <i>EMBO Molecular Medicine</i> , 2022, 14, e14876.	3.3	20
11	Preclinical biodistribution and dosimetry and human biodistribution comparing ¹⁸ F-rhPSMA-7 and single isomer ¹⁸ F-rhPSMA-7.3. <i>EJNMMI Research</i> , 2022, 12, 8.	1.1	4
12	Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. <i>European Urology</i> , 2022, 82, 156-160.	0.9	43
13	Cohort study of oligorecurrent prostate cancer patients: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery.. <i>Journal of Clinical Oncology</i> , 2022, 40, 106-106.	0.8	0
14	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP): An international multicenter study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 42-42.	0.8	1
15	¹⁸ F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1208-1214.	2.8	2
16	Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on ¹⁸ F-rhPSMA-7.3 PET/CT in patients with prostate cancer. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263758.	2.8	5
17	Validation of ¹⁸ F-rhPSMA-7 and ¹⁸ F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1809-1814.	2.8	8
18	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263072.	2.8	28

#	ARTICLE	IF	CITATIONS
19	The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy. <i>EJNMMI Research</i> , 2022, 12, 25.	1.1	10
20	Tumor Sink effect: Myth or Reality?. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.122.264119.	2.8	1
21	PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5043-5043.	0.8	5
22	Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177â€“prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) after radium-223 (²²³Ra): Interim analysis of the RALU study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5040-5040.	0.8	2
23	Cohort study of patients with oligorecurrent prostate cancer: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5009-5009.	0.8	0
24	Matched-Pair Comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Nonâ€“Tumor-Related Uptake and Tumor Positivity. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1082-1088.	2.8	36
25	Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.256263.	2.8	22
26	Positive predictive value and correct detection rate of ¹⁸F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.255661.	2.8	5
27	Diagnostic performance of quantitative and qualitative parameters for the diagnosis of aortic graft infection using [18F]-FDG PET/CT. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2220-2228.	1.4	10
28	PSMA-PET/CTâ€“based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy. <i>European Urology Oncology</i> , 2021, 4, 73-83.	2.6	30
29	Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?. <i>Asian Journal of Urology</i> , 2021, 8, 248-250.	0.5	0
30	Almost 10Âyears of PET/MR attenuation correction: the effect on lesion quantification with PSMA: clinical evaluation on 200 prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 543-553.	3.3	8
31	Important pharmacokinetic parameters for individualization of ¹⁷⁷Luâ€“PSMA therapy: A global sensitivity analysis for a physiologicallyâ€“based pharmacokinetic model. <i>Medical Physics</i> , 2021, 48, 556-568.	1.6	10
32	Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. <i>European Urology</i> , 2021, 79, 343-350.	0.9	128
33	Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2021, 79, 537-544.	0.9	23
34	Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using ¹⁹F/¹⁷⁷Lu-rhPSMA-7.3 and ¹⁷⁷Lu-PSMA I&T. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1106-1111.	2.8	16
35	First Experience Using ¹⁸F-Flubrobenguane PET Imaging in Patients with Suspected Pheochromocytoma or Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 479-485.	2.8	5
36	Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 675-678.	2.8	16

#	ARTICLE	IF	CITATIONS
37	Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. <i>European Urology Focus</i> , 2021, 7, 309-316.	1.6	34
38	Automated synthesis of [18F]Ga-rhPSMA-7/-7.3: results, quality control and experience from more than 200 routine productions. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 4.	1.8	16
39	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1626-1638.	3.3	188
40	Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2925-2934.	3.3	43
41	Detection Efficacy of ¹⁸ F-rhPSMA-7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1719-1726.	2.8	14
42	Nuclear Medicine beyond VISION. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.121.262441.	2.8	5
43	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 640467.	1.3	11
44	Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using ¹⁷⁷ Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5087-TPS5087.	0.8	5
45	Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. <i>BMC Cancer</i> , 2021, 21, 512.	1.1	14
46	A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer. <i>Radiation Oncology</i> , 2021, 16, 82.	1.2	0
47	Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET): An explorative, multicenter study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5066-5066.	0.8	2
48	Prostate-specific Membrane Antigen PET in Prostate Cancer. <i>Radiology</i> , 2021, 299, 248-260.	3.6	38
49	PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1747-1750.	2.8	16
50	Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study. <i>Journal of Urology</i> , 2021, 205, 1663-1670.	0.2	22
51	Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4377-4385.	3.3	114
52	[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. <i>EJNMMI Research</i> , 2021, 11, 70.	1.1	11
53	Value of PET imaging for radiation therapy. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 326-343.	0.3	2
54	Value of PET imaging for radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-23.	1.0	16

#	ARTICLE	IF	CITATIONS
55	Feasibility and Outcome of PSMA-PET-Based Dose-Escalated Salvage Radiotherapy Versus Conventional Salvage Radiotherapy for Patients With Recurrent Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 715020.	1.3	9
56	Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy? An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer. <i>Cancers</i> , 2021, 13, 3429.	1.7	8
57	Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7431.	1.8	25
58	Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷ Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). <i>Journal of Nuclear Medicine</i> , 2021, 62, 1447-1456.	2.8	14
59	The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262471.	2.8	5
60	PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy. <i>EJNMMI Research</i> , 2021, 11, 76.	1.1	12
61	Nomograms to predict outcomes after ¹⁷⁷ Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1115-1125.	5.1	120
62	PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 88-91.	2.8	21
63	First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.249029.	2.8	15
64	Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 3963-3971.	0.6	6
65	An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligands. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 33-37.	0.3	1
66	A population-based method to determine the time-integrated activity in molecular radiotherapy. <i>EJNMMI Physics</i> , 2021, 8, 82.	1.3	10
67	Matched-Pair Comparison of ⁶⁸ Ga-PSMA-11 PET/CT and ¹⁸ F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 51-57.	2.8	161
68	Can the Injected Dose Be Reduced in ⁶⁸ Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 189-193.	2.8	19
69	Prostate-Specific Membrane Antigen-Guided Surgery. <i>Journal of Nuclear Medicine</i> , 2020, 61, 6-12.	2.8	31
70	Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 9-15.	3.3	67
71	Histologically Confirmed Diagnostic Efficacy of ¹⁸ F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 710-715.	2.8	34
72	Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, ¹⁸ F-rhPSMA-7, in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 702-709.	2.8	38

#	ARTICLE	IF	CITATIONS
73	Deep neural network for automatic characterization of lesions on ⁶⁸ Ga-PSMA-11 PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 603-613.	3.3	66
74	¹⁸ F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. Journal of Nuclear Medicine, 2020, 61, 696-701.	2.8	67
75	Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. Journal of Nuclear Medicine, 2020, 61, 1037-1042.	2.8	19
76	Radiohybrid Ligands: A Novel Tracer Concept Exemplified by ¹⁸ F- or ⁶⁸ Ga-Labeled rhPSMA Inhibitors. Journal of Nuclear Medicine, 2020, 61, 735-742.	2.8	76
77	Double-strand breaks in lymphocyte DNA of humans exposed to [¹⁸ F]fluorodeoxyglucose and the static magnetic field in PET/MRI. EJNMMI Research, 2020, 10, 43.	1.1	4
78	Efficacy and Safety of ¹⁷⁷ Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. European Urology, 2020, 78, 148-154.	0.9	39
79	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [⁶⁸ Ga]PSMA-PET-guided metastasis-directed therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2328-2338.	3.3	13
80	Early Prostate-Specific Antigen Changes and Clinical Outcome After ¹⁷⁷ Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 1476-1483.	2.8	34
81	Incidental Finding of Colon Carcinoma Related to High Uptake in ¹⁸ F-PSMA-1007 PET. Clinical Nuclear Medicine, 2020, 45, 561-562.	0.7	3
82	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. BMC Cancer, 2020, 20, 362.	1.1	20
83	A rare case of polyostotic fibrous dysplasia detected on ¹⁸ F-rhPSMA-7 PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2927-2929.	3.3	1
84	Pre-test ⁶⁸ Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy – validation of a prediction model. EJNMMI Research, 2020, 10, 6.	1.1	5
85	Influence of sampling schedules on [¹⁷⁷ Lu]Lu-PSMA dosimetry. EJNMMI Physics, 2020, 7, 41.	1.3	27
86	Impact of ⁶⁸ Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. Journal of Clinical Oncology, 2020, 38, 292-292.	0.8	2
87	Impact of ⁶⁸ Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings. Journal of Clinical Oncology, 2020, 38, 26-26.	0.8	0
88	Modeling and Predicting Tumor Response in Radioligand Therapy. Journal of Nuclear Medicine, 2019, 60, 65-70.	2.8	41
89	¹⁸ F-fluciclovine PET-CT and ⁶⁸ Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncology, The, 2019, 20, 1286-1294.	5.1	338
90	Exceptional 4-year response to ¹⁷⁷ Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2212-2213.	3.3	5

#	ARTICLE	IF	CITATIONS
91	What is the best PET target for early biochemical recurrence of prostate cancer?â€œAuthorsâ€™ reply. <i>Lancet Oncology</i> , The, 2019, 20, e609-e610.	5.1	4
92	Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in ¹⁷⁷ Luâ€PSMA therapy. <i>Medical Physics</i> , 2019, 46, 5861-5866.	1.6	11
93	Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. <i>Journal of Nuclear Medicine</i> , 2019, 60, 13S-19S.	2.8	172
94	Whole-Body [¹⁸ F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2019, 191, 289-297.	0.7	15
95	qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using ⁶⁸ Ga-PSMA11 PET/CT. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1277-1283.	2.8	82
96	Whole-Body [¹⁸ F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, 58, 68-76.	0.3	20
97	Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 76, 517-523.	0.9	81
98	The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model. <i>Scientific Reports</i> , 2019, 9, 20041.	1.6	28
99	Pitfalls in Ga-68-PSMA-PET/CT: incidental finding of parathyroid adenoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1041-1041.	3.3	9
100	Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with ¹⁷⁷ Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 920-926.	0.9	206
101	Early Experience of Rechallenge ¹⁷⁷ Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 644-648.	2.8	29
102	Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 159-171.	1.9	62
103	Practice changing for prostate cancer: a vision of the future. <i>Nature Reviews Urology</i> , 2019, 16, 71-72.	1.9	6
104	^{99m} Techneium-based Prostate-specific Membrane Antigenâ€radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 75, 659-666.	0.9	195
105	⁶⁸ Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. <i>Journal of Urology</i> , 2019, 202, 1174-1181.	0.2	33
106	Evaluation of SUV normalized by lean body mass (SUL) in ⁶⁸ Ga-PSMA11 PET/CT: a bi-centric analysis. <i>EJNMMI Research</i> , 2019, 9, 103.	1.1	11
107	A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. <i>European Radiology Experimental</i> , 2019, 3, 41.	1.7	55
108	RESIST-PC phase 2 trial: ¹⁷⁷ Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5028-5028.	0.8	11

#	ARTICLE	IF	CITATIONS
109	Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy.. Journal of Clinical Oncology, 2019, 37, 15-15.	0.8	8
110	Prospective head-to-head comparative phase 3 study between ¹⁸ F-fluciclovine and ⁶⁸ Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5014-5014.	0.8	0
111	Reply by Authors. Journal of Urology, 2019, 202, 1181-1181.	0.2	0
112	Efficacy, Predictive Factors, and Prediction Nomograms for 68 Ga-labeled Prostate-specific Membrane Antigenâ€“ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. European Urology, 2018, 73, 656-661.	0.9	129
113	Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands. World Journal of Urology, 2018, 36, 603-608.	1.2	28
114	The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for ¹⁷⁷ Lu-Labeled PSMA Peptides. Journal of Nuclear Medicine, 2018, 59, 929-933.	2.8	54
115	⁶⁸ Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging. Journal of Nuclear Medicine, 2018, 59, 1406-1411.	2.8	106
116	Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics, 2018, 38, 200-217.	1.4	262
117	Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis. EJNMMI Research, 2018, 8, 17.	1.1	6
118	Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007. EJNMMI Research, 2018, 8, 30.	1.1	33
119	Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer. Current Opinion in Urology, 2018, 28, 191-196.	0.9	16
120	Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 602-612.	3.3	107
121	The use of PET/CT in prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 4-21.	2.0	70
122	Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. Journal of Experimental Medicine, 2018, 215, 159-175.	4.2	121
123	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Research, 2018, 8, 96.	1.1	58
124	Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology, The, 2018, 19, e696-e708.	5.1	90
125	Multimodal imaging for radiation therapy planning in patients with primary prostate cancer. Physics and Imaging in Radiation Oncology, 2018, 8, 8-16.	1.2	8
126	Gallium-68 HBED-CC-PSMA Positron Emission Tomography/Magnetic Resonance Imaging for Prostate Fusion Biopsy. Clinical Genitourinary Cancer, 2018, 16, 245-247.	0.9	8

#	ARTICLE	IF	CITATIONS
127	One-Stop-Shop Whole-Body ⁶⁸ Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1850-1856.	2.8	55
128	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. <i>American Journal of Roentgenology</i> , 2018, 211, 286-294.	1.0	25
129	Positron emission tomography imaging in urological oncology: Current aspects and developments. <i>International Journal of Urology</i> , 2018, 25, 912-921.	0.5	10
130	Accuracy of ⁶⁸ Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5001-5001.	0.8	6
131	Oncological and postoperative outcome of salvage PSMA-radioguided surgery in recurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 270-270.	0.8	0
132	Clinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 206-206.	0.8	1
133	A PET for All Seasons: 18 F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis?. <i>European Urology</i> , 2017, 71, 934-935.	0.9	0
134	Detection Efficacy of Hybrid ⁶⁸ Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1081-1087.	2.8	66
135	Value of ¹¹¹ In prostate-specific membrane antigen (¹¹¹ In-PSMA) radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. <i>BJU International</i> , 2017, 120, 40-47.	1.3	88
136	Development of standardized image interpretation for ⁶⁸ Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1622-1635.	3.3	91
137	Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using ⁶⁸ Ga-PSMA PET/CT. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1632-1637.	2.8	33
138	⁶⁸ Ga-PSMA PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. <i>Prostate</i> , 2017, 77, 920-927.	1.2	89
139	From NETTER to PETER: PSMA-Targeted Radioligand Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 9-10.	2.8	14
140	Prospective head-to-head comparison of ¹¹ C-choline-PET/MR and ¹¹ C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2179-2188.	3.3	35
141	PSMA Ligands for PET Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1545-1552.	2.8	165
142	Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). <i>BMC Cancer</i> , 2017, 17, 361.	1.1	67
143	⁶⁸ Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1949-1955.	2.8	27
144	Radiation Dosimetry for ¹⁷⁷ Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2017, 58, 445-450.	2.8	144

#	ARTICLE	IF	CITATIONS
145	Preclinical Evaluation and First Patient Application of ^{99m} Tc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 235-242.	2.8	170
146	Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 344-357.	1.8	3
147	PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?. <i>Theranostics</i> , 2017, 7, 2046-2047.	4.6	12
148	Multiparametric ^{18F} FDG PET/MR follow-up in a patient with autoimmune pancreatitis. <i>European Journal of Hybrid Imaging</i> , 2017, 1, 11.	0.6	2
149	^{11C} -choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer. <i>Oncotarget</i> , 2017, 8, 66516-66527.	0.8	25
150	PSMA-targeted imaging of prostate cancer: evolution of a success story. <i>Asian Journal of Andrology</i> , 2017, 19, 388.	0.8	0
151	[^{11C}]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy. <i>Oncotarget</i> , 2016, 7, 63747-63757.	0.8	9
152	PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e549-e552.	0.9	19
153	Biodistribution and radiation dosimetry of ⁶⁸ Ga-PSMA HBED CCâ€”a PSMA specific probe for PET imaging of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1962-1970.	3.3	66
154	Systemic Radioligand Therapy with ¹⁷⁷ Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 382-391.	0.2	166
155	⁶⁸ Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Blockâ€”Early or Too Early to Draw Conclusions?. <i>European Urology</i> , 2016, 70, 938-940.	0.9	13
156	Value of ⁶⁸ Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1713-1719.	2.8	213
157	Value of diffusion-weighted MR imaging in the diagnosis of lymph node metastases in patients with cholangiocarcinoma. <i>Abdominal Radiology</i> , 2016, 41, 1937-1941.	1.0	24
158	Prospective evaluation of [^{11C}]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2105-2113.	3.3	42
159	⁶⁸ Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. <i>Cancer Imaging</i> , 2016, 16, 14.	1.2	171
160	Comparison of bone scintigraphy and ⁶⁸ Ga-PSMA PET for skeletal staging in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2114-2121.	3.3	302
161	Simultaneous ⁶⁸ Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. <i>European Urology</i> , 2016, 70, 829-836.	0.9	456
162	First Experience with Chemokine Receptor CXCR4â€”Targeted PET Imaging of Patients with Solid Cancers. <i>Journal of Nuclear Medicine</i> , 2016, 57, 741-746.	2.8	109

#	ARTICLE	IF	CITATIONS
163	Diagnostic Efficacy of ⁶⁸ Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. <i>Journal of Urology</i> , 2016, 195, 1436-1443.	0.2	659
164	⁶⁸ Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 367-371.	2.8	112
165	Current use of PSMA- ⁶⁸ PET in prostate cancer management. <i>Nature Reviews Urology</i> , 2016, 13, 226-235.	1.9	469
166	Fully integrated whole-body [¹⁸ F]-fludeoxyglucose positron emission tomography/magnetic resonance imaging in therapy monitoring of giant cell arteritis. <i>European Heart Journal</i> , 2016, 37, 576-576.	1.0	9
167	Imaging for Prostate Cancer Recurrence. <i>European Urology Focus</i> , 2016, 2, 139-150.	1.6	36
168	Re: Lars Bud-Åus, Sami-Ramzi Leyh-Bannurah, Georg Salomon, et al. Initial Experience of ⁶⁸ Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. <i>Eur Urol</i> 2016;69:393-6. <i>European Urology</i> , 2016, 70, e37-e38.	0.9	9
169	<i>In vivo</i> molecular imaging of chemokine receptor ⁴ CXCR expression in patients with advanced multiple myeloma. <i>EMBO Molecular Medicine</i> , 2015, 7, 477-487.	3.3	180
170	Visualization of stress fractures of the foot using PET-MRI: a feasibility study. <i>European Journal of Medical Research</i> , 2015, 20, 99.	0.9	22
171	Prostate-specific Membrane Antigen- ⁶⁷ radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. <i>European Urology</i> , 2015, 68, 530-534.	0.9	192
172	[¹¹¹ In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. <i>EJNMMI Research</i> , 2015, 5, 68.	1.1	88
173	⁶⁸ Ga- and ¹⁷⁷ Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1169-1176.	2.8	432
174	Evaluation of ¹⁸ F-Fluoride PET/MR and PET/CT in Patients with Foot Pain of Unclear Cause. <i>Journal of Nuclear Medicine</i> , 2015, 56, 430-435.	2.8	25
175	Evaluation of Hybrid ⁶⁸ Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 668-674.	2.8	907
176	Discrimination Between Brown and White Adipose Tissue Using a 2-Point Dixon Water- ¹ Fat Separation Method in Simultaneous PET/MRI. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1742-1747.	2.8	45
177	⁶⁸ Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. <i>Abdominal Imaging</i> , 2015, 40, 1769-1771.	2.0	74
178	Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy. <i>Anticancer Research</i> , 2015, 35, 5679-85.	0.5	29
179	PET/MR in Oncology: Non- ¹⁸ F-FDG Tracers for Routine Applications. <i>Journal of Nuclear Medicine</i> , 2014, 55, 25S-31S.	2.8	15